Latest Oligodendroglioma Stories
Findings show that damage to surrounding tissue may play role in determining high-grade glioma patients' long-term outcome.
Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy.
Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults.
Scientists at Duke Cancer Institute have discovered that genetic mutations found in brain tumors can alter tumor metabolism.
Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer.
A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer.
For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer.
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.